DAY ONE / MARCH 27, 2018
As in industry, disruptive innovation has become a powerful force for change in health care. As a long time ER physician, broadcaster and observer of modern medical culture, Dr. Brian Goldman knows a lot about that. In this keynote, Dr. Goldman defines and explains the concepts behind disruptive innovation, and gives recent examples in of disruption in health care. He talks about the potential impact of disruptive innovation on clinical trials, including the impact of big data on clinical research.
Brian Goldman, ER Physician, Author and Radio Broadcaster (CBC’s White Coat, Black Art)
This session will focus on key drivers of change in the clinical research environment. The panel will discuss how we can adapt to these changes and how patients, healthcare and our economy will be impacted now and in the future.
Jason Field (Moderator), President and CEO, Life Sciences Ontario
Brian Goldman, ER Physician, Author and Radio Broadcaster (CBC’s White Coat, Black Art)
Ed Dybka, Past-President, AstraZeneca Canada Inc., CTO Board Member
Benjamin Haibe-Kains, Scientist, UHN
Bev Heim-Myers, CEO, Huntington Society of Canada
Allan O’Dette, Chief Investment Officer, Ontario Investment Office
Jennifer Zelmer, President and CEO, Azimuth Health Group
Zayna Khayat, Futures Strategist, Saint Elizabeth
Shahira Bhimani, Director, MaRS EXCITE
Francis Plummer, Professor of Medicine and Medical Microbiology, University of Manitoba, and Scientific Director General, National Microbiology Laboratory, Public Health Agency of Canada
Interviewed by Dawn Richards, Director, Patient & Public Engagement, Clinical Trials Ontario
This session will focus on current and emerging trends in clinical trial design, how trials are evolving to meet the changing needs of patients, researchers, regulators and the healthcare system and how we can ensure that patient safety is always protected through stringent ethical frameworks.
Raphael Saginur (Moderator), Chair, Ottawa Health Sciences Research Ethics BoardIntegrating Clinical Trials with Best Practices and Quality Improvement: The Path Forward
Paul Karanicolas, Surgical Oncologist and Scientist, Odette Cancer Centre, Sunnybrook Health Sciences Centre
Ethical Issues in Pragmatic Trials: New Designs, New Challenges
Charles Weijer, Professor and Canada Research Chair in Bioethics, Western University
Rethinking Pragmatic Trials: The Experience of the REaCT Program in Cancer
Dean Fergusson, Senior Scientist & Director, Clinical Epidemiology Program, Ottawa Hospital Research Institute, Professor, Departments of Medicine, Surgery & Epidemiology and Community Medicine, University of Ottawa.
Clinical trials simply don’t happen without participants. What do we understand about the specific opportunities and challenges that exist for people who wish to find and join a clinical trial? We’ll hear from a patient, caregiver, health charity and family physician who will shed light on those experiences, and present some initiatives and resources that have been created to help potential participants find and join a clinical trial.
Making it Easier for Patients to Understand and Participate in Clinical Trials
Bev Heim-Myers (Moderator), CEO, Huntington Society of Canada
How Clinical Trial Reform Can Help People With Lethal Diseases Extend Their Lives and Live Well
John-Peter Bradford, CEO, Life Saving Therapies Network
Finding out About Trials in Family Medicine: How Family Practice Based Research Networks and their Data Can Help
Michelle Greiver, Acting Director, University of Toronto Practice-Based Research Network (UTOPIAN), Adjunct Scientist, Institute for Clinical Evaluative Sciences
Navigating Through Neuroblastoma and Therapy Induced Myelodysplastic Syndrome
Kirby Kim, Caregiver Representative and Contributing Member, Neuroblastoma Canada
A Patient’s Perspective Navigating the Clinical Trial Process – Challenges and Positive Outcomes
Tina Ceroni, Clinical Trials Ontario Patient and Public Engagement Advisory Group Member
Clinical Trial Support Center Services: Patient Experiences Using the Information Resource Center
Sarah Khan, Patient Education & Support Manager – Ontario Region, Leukemia & Lymphoma Society of Canada – Clinical Trials Support Centre
DAY TWO / MARCH 28, 2018
An examination of the current global operating environment for clinical research and specific areas where patient engagement practices and initiatives are being implemented. Measures of the expected and actual return on patient engagement will be presented. This session will also explore anticipated landscape changes — both short- and long-term — as patient engagement practices become more deeply embedded in the clinical research process.
Ken Getz, Director, Sponsored Research Programs and Research Associate Professor, Tufts Center for the Study of Drug Development
Patient engagement with clinical trials remains a hot topic, and for many, uncharted territory. A variety of perspectives (patient, pharma, academic, and government-funded) will share their efforts related to ensuring patients and caregivers are engaged with clinical trials, including the evaluation of that engagement. National and international initiatives demonstrate a breadth of ways to leverage patient and caregiver voices with clinical trials, all aimed at creating more robust trials and outcomes.
Ken Getz (Moderator), Director, Sponsored Research Programs and Research Associate Professor, Tufts Center for the Study of Drug Development
Patient Group Pathways to Cancer Clinical Trials
Barry Stein, President and CEO, Colorectal Cancer Canada
Chamber Music to Symphony: Integrating Patient Community Insights in Medicine Development Through a Cycle of Internal and External Engagement
Roslyn Schneider, Global Patient Affairs Lead, Pfizer
Advancing the Science of Patient Engagement Through Evaluation
Julia Abelson, Professor, Health Research Methods, Evidence, and Impact, McMaster University
Including Patients in the CADTH Scientific Advice Program: Ask, Listen, Advise
Ken Bond, Director, Patient Engagement, Ethics and International Affairs, Canadian Agency for Drugs and Technologies in Health
Patient Engagement and a Clinical Study in the Making – From Theory to Practice
Chantal Lacasse, Senior Clinical Operations Manager, Clinical Research, AbbVie
In a fast evolving era of big data, tremendous opportunities exist to advance our abilities to understand, prevent and treat disease. This session will highlight potential strategies for leveraging existing data and developing new sources and infrastructure to improve healthcare. The session will also explore associated privacy and security issues and how they may be addressed responsibly and efficiently to advance research opportunities.
Genomics in a Global Learning Health System
Peter Goodhand (Moderator), President of the Ontario Institute for Cancer Research and Executive Director of the Global Alliance for Genomics and Health
Realizing the Opportunities: Using Ontario’s Health Data as a Driver to Improve Healthcare and Outcomes
Michael Schull, President and CEO, Institute of Clinical Evaluative Sciences
Reza Samavi, Assistant Professor, Department of Computing and Software, MSc eHealth Program Coordinator, McMaster University
How Can we Build a Health Data Ecosystem in Canada?
Michael Duong, Director, Medical Affairs – Evidence Generation, Roche
Regulating the Use of Personal Health Information in Big Data Research
Joshua Shaw, Health Policy Analyst, Information and Privacy Commissioner of Ontario
The clinical trials community continues to advance ways to streamline the conduct of clinical trials and make Ontario and Canada better locations to conduct trials. This session will review recent advances in streamlining and opportunities for continued improvement in clinical trial conduct.
Making the Case for a Single pan-Canadian Research Ethics Review for Childhood Cancer Studies
James Witlock, Division Head and Women’s Auxiliary Millennium Chair in Haematology/Oncology, The Hospital for Sick Children, Senior Associate Scientist in the Child Health Evaluative Sciences Program, SickKids Research Institute
Innovative Approaches to Multi-centre Academic Clinical Trials in Canada: Accomplishing More with Less!
Lauren Kelly, Clinical Trialist, George & Fay Yee Centre for Healthcare Innovation
Streamlining the Review and Resolution of Privacy Issues
Holly Longstaff, Research Privacy Advisor, Provincial Health Services Authority, Ethicist, BC Cancer Research Ethics Board
How do we Forge Ahead? Key Learnings from “No Site Left Behind” Workshop
A review of key learning and opportunities ahead identified in the CTO pre-conference workshop that focused on strategies for maximizing clinical trial start-up efficiency
Karri Venn, President, Research, LMC|Manna Research